AbstrAct
Acute respiratory distress syndrome (ARDS) is among the most challenging disease processes faced in critical care medicine. This syndrome is defined as a spectrum of persistent lung inflammation with increased vascular permeability, one end of which comprises of acute lung injury (ALI) characterized by acute onset, bilateral infiltrates consistent with pulmonary edema, a ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2/FiO2) between 201 and 300 mmHg and no clinical evidence of an elevated left atrial pressure. The other end of spectrum comprises of more severe acute respiratory distress syndrome. The definition of ARDS is the same as ALI except that the hypoxemia is worse (PaO 2 /FiO 2 ≤200 mmHg). Although more than 60 causes of ARDS have been identified, yet pneumonia, sepsis, trauma are the most common etiologies. The diagnosis is most of the time based on presence of risk factors, clinical features and radiology. No specific therapy for ARDS exists. Treatment of the underlying condition is essential, along with supportive care and appropriate ventilator and fluid management. With the development of the NIH-sponsored ARDS Clinical Trials Network, large well-controlled trials of ARDS therapies have been completed, but the only treatment found to improve survival among these trials is a mechanical ventilation strategy using low tidal volumes.
IntroductIon
Advances in positive pressure mechanical ventilation in the 1960s led to the recognition of a distinct form of respiratory failure with acute injury to both lungs. Military clinicians working in surgical hospitals in Vietnam called the problem 'shock lung'. In civilian hospitals, this same form of respiratory failure was later known as the adult respiratory distress syndrome (ARDS) 1 . ARDS is among the most challenging disease processes faced in critical care medicine. defInItIon ARDS refers to the severe end of the spectrum of "acute lung injury". For more than 20 years, progress in understanding the epidemiology and clinical features of acute lung injury and ARDS was hampered by lack of uniform definitions for these two terms. In 1994, the American-European Consensus Conference on ARDS issued the following definitions that have been widely adopted by clinicians and researchers 2, 3 .
Acute lung injury -Acute lung injury (ALI) is defined as a syndrome of acute and persistent lung inflammation with increased vascular permeability. ALI is characterized by four clinical features:
• Acute onset
• Bilateral infiltrates consistent with pulmonary edema
• A ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO 2 /FiO 2 ) between 201 and 300 mmHg, regardless of the level of positive end-expiratory pressure (PEEP). The PaO 2 is measured in mmHg and the FiO 2 is expressed as a decimal between 0.21 and 1.00.
• No clinical evidence for an elevated left atrial pressure. If measured, the pulmonary capillary wedge pressure is 18 mmHg or less.
Acute respiratory distress syndrome -The definition of ARDS is the same as ALI except that the hypoxemia is worse (PaO 2 /FiO 2 ≤200 mmHg), regardless of the level of PEEP.
etIology
More than 60 causes of ARDS have been identified. Additional causes continue to emerge as adverse pulmonary reactions to new therapies are discovered. Although the list of possible causes is long, epidemiologic studies have shown that most episodes of ARDS are associated with a few common causes or predisposing conditions, singly or in combination 4 ( Table-1) .
PAthoPhysIology
Normal lung function requires dry, patent alveoli, closely situated to appropriately perfused capillaries. The normal pulmonary capillary endothelium is selectively permeable; serum protein remains intravascular, while fluid crosses the membranes under the control of hydrostatic and osmotic forces. The balance of hydrostatic and oncotic forces normally allows small quantities of fluid into the interstitium, but three mechanisms exist to prevent alveolar edema 5 : a) retained intravascular protein maintains an oncotic gradient favouring reabsorption, b) the interstitial
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ACuTE RESPIRATORy DISTRESS SyNDROME lymphatics can return large quantities of fluid to the circulation and c) tight junctions between alveolar epithelial cells prevent leakage into the air spaces.
Clinical ARDS occurs primarily as the result of inflammatory injury to the alveoli producing diffuse alveolar damage. Inflammatory injury occurs as a result of release of pro-inflammatory cytokines such as tumor necrosis factor, interleukin IL-1, IL-6, and IL-8 in response to any of a variety of precipitants 6, 7 . Neutrophils recruited to the lungs become activated, and release toxic mediators such as reactive oxygen species and proteases which damage the capillary endothelium and alveolar epithelium resulting in loss of normal barriers to alveolar edema. Protein escapes from the vascular space resulting in loss of oncotic gradient favoring resorption of fluid. Fluid pours into the interstitium and overwhelms the capacity of the lymphatics. The result is that the air spaces fill with bloody, proteinaceous edema fluid and debris from degenerating cells. Functional surfactant is lost, resulting in alveolar collapse. Lung injury has numerous consequences including impairment of gas exchange, decreased lung compliance, and increased pulmonary arterial pressure.
Pathological Stages
Patients with ARDS tend to progress through three relatively discrete pathologic stages 8 . The initial "exudative" stage, characterized by diffuse alveolar damage, gives way over the first week to a "proliferative" stage, characterized by resolution of pulmonary edema and by proliferation of type II alveolar cells, squamous metaplasia, interstitial infiltration by myofibroblasts, and early deposition of collagen. Some patients progress to a third "fibrotic" stage, characterized by obliteration of normal lung architecture, diffuse fibrosis, and cyst formation.
clInIcAl feAtures
Despite a variety of precipitating factors, most patients follow a fairly stereotypical course, characterized by severe initial hypoxemia, followed by a prolonged need for mechanical ventilation. Early clinical features related to the precipitant of ARDS as well as the effects of diffuse alveolar damage. As examples, fever and hypotension from septic shock, or severe abdominal pain from pancreatitis, may dominate the early clinical course. Pulmonary dysfunction typically develops within 24 to 48 hours of the inciting event 4 . Patients develop rapidly worsening tachypnea, dyspnea, and hypoxemia requiring high concentrations of supplemental oxygen; dry cough and chest pain may also be present. The physical examination usually reveals cyanosis, tachycardia, tachypnea, and diffuse rales in the chest. Mechanical ventilation is almost universally required.Laboratory findings are nonspecific and may include leukocytosis, evidence of disseminated intravascular coagulation (DIC), and lactic acidosis. Arterial blood gases usually show an acute respiratory alkalosis, an elevated alveolar-arterial oxygen gradient, and severe hypoxemia reflecting right to left shunt physiology.
dIAgnostIc studIes

Radiographic Imaging
Radiographic studies have long been a mainstay of the diagnosis of ALI and ARDS. In the initial description of the syndrome, the chest radiograph typically shows diffuse, fluffy alveolar infiltrates with prominent air bronchograms. The diagnosis of ARDS does not require widespread or severe opacification -bilateral infiltrates of any severity are sufficient 9 . Similar abnormalities can be seen in other diseases, such as diffuse pulmonary hemorrhage and congestive heart failure. The absence of pulmonary venous congestion, kerley B lines, cardiomegaly, and pleural effusions (abnormalities normally attributed to congestive heart failure) favors the diagnosis of ARDS. Although chest radiography is inherent to the diagnosis of ARDS, differentiation between pulmonary edema on the grounds of increased hydrostatic pressure and that of increased capillary leak edema may at times may be difficult. Computed tomography generally demonstrates patchy abnormalities with increased density in dependent lung zones. Computed tomography is also quite helpful in elucidating the progression of ARDS, after 7-10 days, sub pleural cysts, bullae, and emphysematous cysts are more commonly seen.
Edema fluid analysis -In an analysis of pulmonary edema fluid from patients with low and high pressure pulmonary edema as stratified by history and P PW, one group reported that the ratio of protein in edema fluid to plasma was consistently greater than 0.6 in patients with increased permeability edema, and consistently, below 0.6 in those with cardiogenic edma 10, 11 . Although not widely used, protein fluid analysis can be extremely helpful in cases where ALI or ARDS coexists with left ventricular dysfunction, and routine measures to exclude congestive heart failure as etiology of hypoxemia prove difficult.
Brain natriuretic peptide-Measurement of plasma BNP may be helpful in distinguishing ARDS from hemodynamic pulmonary edema in a minority of patients. A prospective cohort study evaluated the diagnostic characteristics of BNP among patients who had ARDS/ALI (n=33) or hemodynamic pulmonary edema 12 . A BNP level less than 100 pg/mL identified ARDS/ALI with a sensitivity, specificity, positive predictive value, and negative predictive value of 27, 95, 90, and 44 percent, respectively. This suggests that a BNP level below 100 pg/mL may distinguish ARDS/ ALI from heart failure, but higher levels can neither confirm heart failure nor exclude ARDS/ALI in critically ill patients 12 .
Echocardiography-Many clinicians now use transthoracic echocardiography as the next diagnostic step if the mechanism of edema formation cannot be determined with confidence by clinical evaluation and measurement of the plasma BNP level. Detecting severe aortic or mitral valve dysfunction or a severely reduced left ventricular ejection fraction favors hemodynamic over permeability edema. Heart failure due to diastolic dysfunction and volume overload due to acute renal failure may be difficult to exclude because their left heart function will appear normal. Thus, echocardiography can be inconclusive, particularly if clinical suspicion of elevated pulmonary microvascular pressure is moderate or high.
Pulmonary artery catheterization -Pulmonary artery catheterization should be considered if the distinction between hemodynamic and permeability pulmonary edema remains uncertain after clinical evaluation, plasma BNP measurement, and echocardiography. Confident measurement of a pulmonary capillary wedge pressure greater than 18 mm Hg strongly suggests that abnormal pulmonary microvascular pressure is contributing to pulmonary edema formation, although high pulmonary capillary wedge pressures should be interpreted with caution if patients are being managed with high levels of positive end-expiratory pressure (PEEP). However, an elevated wedge pressure does not exclude the possibility of ALI. It is estimated that as many as 20 percent of patients with ARDS have concomitant left ventricular dysfunction 13 . Continuous hemodynamic monitoring by means of a pulmonary artery catheter has never been shown to confer clinical benefit in the management of ARDS. Indeed, a recent multi-center trial found no improvement in survival or organ function, but more complications in patients with ARDS who were randomized to monitoring by pulmonary artery catheterization versus monitoring by central venous catheterization 14 . Consequently, if pulmonary artery catheterization is performed to diagnose left ventricular dysfunction, the catheter should be removed after initial evaluation is complete.
Bronchoscopy & lung biopsy
Though ARDS is a clinical syndrome which can be precipitated from numerous primary insults, there exist several distinct disease processes which can mimic the radiographic and clinical symptomatology of ARDS. In patients with respiratory distress, yet without risk factors for ALI, bronchoscopy with bronchoaveloar lavage (BAL) or lung biopsy may help to exclude treatable disease like pneumocytis pneumonia, acute eosinophilic pneumonia, acute cryptogenic organizing pneumonia, acute hypersensitivity pneumonitis and diffuse alveolar hemorrhage
MAnAgeMent
No specific therapy exists. for ARDS Treatment of the underlying condition is essential, along with supportive care and appropriate ventilator and fluid management. Because infection is often the underlying cause of ARDS, careful assessment of the patient for infected sites and early institution of appropriate antibiotic therapy is essential. In some instances, removal of intravascular lines, drainage of infected fluid collections, or surgical debridement or resection of an infected site, such as the ischemic bowel, may be necessary because sepsis-associated ARDS does not resolve without such management. Other important interventions in sepsis might include early goal-directed therapy, tight glucose control, use of drotrecogin alpha in appropriate patients with severe sepsis, and avoidance of complications by means of prophylaxis for deep venous thrombosis and stress ulcer. An important advance in this field has been the establishment of an ARDS network supported by the NIH that includes 10 centres, 24 hospitals, and 75 intensive care units and that provides the infrastructure for well-designed, multicenter, randomized trials of potential new therapies for ARDS.
MechAnIcAl ventIlAtIon
Ventilator-associated lung injury may be an important cause of poor clinical outcomes in patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). As a result, strategies of mechanical ventilation that reduce the incidence and severity of ventilator-associated lung injury are being sought.
Low tidal volume ventilation
Low tidal volume ventilation (LTVV) is also referred to as lung protective ventilation. The rationale for this approach is that smaller tidal volumes are less likely to generate alveolar over distension, one of the principle causes of ventilator-associated lung injury. The preponderance of evidence suggests that LTVV improves mortality, as well as other clinically important outcomes in patients with ARDS.
ARDS network (ARDSNet) multicenter randomized trial investigated low versus traditional tidal volumes in ALI and ARDS 15 . Patients in the experimental arm received ventilation with 6 ml/ kg of predicted IBW or less to maintain their plateau pressure (P plat ) below 30 cm H 2 O; patients in the traditional arm received 12 ml/kg or less, keeping their P plat below 50 cm H 2 O. 861 patients were studied and the trial was stopped early due to the reduced mortality observed in the low tidal volume group. Whereas 40 percent of patient of patients receiving traditional tidal volumes died, only 31 percent of those receiving low tidal volumes died, and the latter group had an increase in the number of ventilator -free days 15 . A 2004 meta-analysis of five randomized trials (1202 patients, 861 from ARDSNet trial) also found that LTVV significantly improved 28 day mortality compared to conventional ventilation (relative risk 0.74, 95% CI 0.61-0.88) 16 .
LTVV is generally well tolerated. It was not associated with any clinically important adverse outcomes in the ARDSNet trial 15 . LTVV frequently requires permissive hypercapnic ventilation (PHV), a ventilatory strategy that accepts alveolar hypoventilation in order to maintain a low alveolar pressure and minimize the complications of alveolar overdistension like ventilatorassociated lung injury. Hypercapnia and respiratory acidosis are a consequence of this strategy. Hypercapnic respiratory acidosis is generally well tolerated consequence of LTVV. The degree of hypercapnia can be minimized by using the highest respiratory rate that does not induce auto-PEEP and shortening the ventilator tubing to decrease dead space 17 .
LTVV can be effectively performed using a protocol similar to that used in the ARDSNet trial 15 :-
•
The initial tidal volume is set to 8 ml/kg IBW and the initial respiratory rate is set to meet the patient's minute ventilation requirements.
• Over the next one to three hours, the tidal volume is reduced to 7 ml/kg IBW and then 6 ml/kg IBW. The IBW is calculated using the following equations: for females: IBW = 45.5+0.9 (ht in cm-152.4), for males: IBW = 50 + 0.9 (ht in cm-152.4) 59.42 where IBW is expressed in kg and height is expressed in cm.
• The respiratory rate is increased (up to a maximum of 35 breaths/ minute) as the tidal volume is decreased, so that the ventilator continues to deliver the patient's entire minute ventilation.
• Subsequent tidal volume adjustments are made on the basis of the plateau airway pressure, as measured using a 0.5 second inspiratory breath hold. The plateau airway pressure is checked at least every four hours and after each change in PEEP or tidal volume.
• The goal plateau airway pressure is ≤30 cmH2O. When the plateau airway pressure is >30 cmH2O, the tidal volume is decreased in 1 mL/ kg IBW increments to a minimum of 4 mL/kg IBW. A threshold plateau airway pressure below which safety is certain has not been determined. The goal plateau airway pressure of ≤30 cmH2O is based on the ARDSNet trial . It seems reasonable to strive to keep the plateau airway pressure as low as possible, using LTVV even if the plateau airway pressure is already below 30 cmH2O 18 .
• A reasonable oxygenation goal during LTVV is an arterial oxygen tension (PaO2) between 55 and 80 mmHg or an oxyhemoglobin saturation (SpO2) between 88 and 95 percent 15 . This is typically achieved by adjusting the fraction of inspired oxygen (FiO2) and the applied PEEP.
Positive end-expiratory pressure (PEEP)
PEEP has been demonstrated to increase functional residual capacity and appears to recruit collapsed alveoli, thus reducing the fraction of nonaerated lung and improving oxygenation 19, 20 . It may be that PEEP decreases ventilator induced lung injury by decreasing mechanical shear forces cased by respective opening and closing of alveoli in atelectatic regions of the lung, or by reducing stretch between aerated and nonaerated regions 21 .
The optimal level of PEEP in the treatment of ALI has also been a topic of considerable investigation. To attempt to determine whether tidal volume or PEEP was of greater importance on mortality, ARDSNet conducted a multicenter randomized trial comparing lower-versus higher-PEEP algorithms for the management of patients with ALI and ARDS 21 . Both groups were ventilated with a lung protective volume controlled strategy, using tidal volumes of 6 ml/kg IBW or less and maintaining Pplat below 30 cm H2O. There was no difference in clinical outcome whether a lower or higher PEEP pathway was used. Mortality was unchanged between groups, as were the number of days breathing unassisted. Perhaps as importantly, higher levels of PEEP did not impart harm to the 251 patients treated in the experimental arm. Pneumothorax and air leaks occurred with the same frequency in each group, as did circulatory, coagulation, hepatic, or renal failure. It is recommended to manage the applied positive end-expiratory pressure (PEEP) and fraction of inspired oxygen (FiO2) 
non-InvAsIve PosItIve Pressure ventIlAtIon (nIPPv)
NIPPV has been well validated as an effective and intubation sparing intervention for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD) and with cardiogenic pulmonary edema. However, earlier studies of patients with acute respiratory failure randomized either to NIPPV or to conventional oxygen therapy by venturi mask found no significant reduction in intubation rates, mortality, or ICu length of stay for patients receiving NIPPV 22 . In 1988, a study randomized patients with acute hypoxemic respiratory failure, a quarter of whom had ARDS, to either NIPPV or intubation with mechanical ventilation and found NIPPV to be as effective in improving gas exchange 23 . Moreover, the study found a significant decrease in the number of septic complications for patients who avoided intubation, as well as a shorter ICu length of stay. Owing to a lack of convincing benefit for NIPPV over conventional intubation and mechanical ventilation in patients with ARDS, its routine use cannot be recommended.
exPerIMentAl therAPIes
In certain patients with severe ARDS, even validated low tidal volume ventilation approach is unsuccessful. Among the various following strategies employed in this situation, several have been proved to be safe and a few may be as effective as our conventional therapy.
High frequency oscillatory ventilation (HFOV)
HFOV oscillates the lung at set airway pressure, often a pressure higher than that used in conventional pressures or volume controlled ventilation. Theoretically, HFOV avoids both lung over distension and the cyclic collapse/ reexpansion of alveoli, the two mechanisms purported to cause ventilator induced lung injury, by maintaining a constant level of alveolar recruitment 24 . The mechanism of gas exchange in this model of ventilation is not fully understood, but may be due to enhanced axial diffusion of gases. A recent randomized controlled trial found HFOV to have comparable mortality to conventional therapy in patients with ARDS 24 .
Partial liquid ventilation (PLV)
PLV employs perfluorocarbon to fill the lungs to a volume approaching functional residual capacity (FRC) and then gas ventilate the lungs with a mechanical ventilator. Because perflurocarbon is immiscible with aqueous solutions and has a high oxygen and carbondioxide carrying capacity, it theoretically could improve gas exchange, decrease shunt, and increase lung compliance 25 . At this time, PLV can be considered an experimental therapy, and to date it has not been definitively tested against a lung protective ventilation strategy.
Inverse ratio ventilation (IRV)
IRV is pressure cycled or volume cycled ventilation employing a prolonged inspiratory time (I: E ratio > 1) in the hopes of decreasing physiologic dead space and better mixing of alveolar and bronchial gases 26 . Prolonging the inspiratory time can be an effective means of improving oxygenation in some patients with ARDS because the parenchymal abnormalities are heterogeneous, with different areas of the lung requiring more time to open and participate in gas exchange. It can be considered in patients who remain severely hypoxemic despite a high FiO 2 .There are potential harms associated with prolonging the inspiratory time that should be considered. When the inspiratory time is increased, there is an obligatory decrease in the expiratory time. This can lead to air trapping, auto-PEEP, barotrauma, hemodynamic instability, and decreased oxygen delivery. In addition, a prolonged inspiratory time may require significant sedation or neuromuscular blockade, particularly if the inspiratory time surpasses the expiratory time (inverse ratio ventilation).
Extracorporeal gas exchange for oxygenation or co 2 removal (ECMO/ ECCO 2 R)
ECMO/ECCO 2 R for either oxygenation or carbon dioxide removal from the bloodstream offers theoretical advantages to patients with ARDS, but several clinical trials have shown it to be ineffective. As such, both ECMO and ECCO 2 R are best regarded as salvage or heroic therapy for patients in whom all other measures have failed.
Intravenous Oxygenator (IVOX)
One technological advancement generating interest for improved therapy in ARDS is the intravenous oxygenator (IVOX0). This is a hollow-fiber membrane oxygenator mounted on a central catheter and inserted into the patient's superior vena cava. In theory, this device is an intracorporeal extra pulmonary gas exchanger. Although no prospective clinical trial using IVOX has yet been published, a phase II trial to establish its safety in patients with ARDS disclosed 50 percent short term and 60 percent overall morality 27 .
Prone position
Because ALI causes inhomogeneous distribution of pulmonary consolidation, often with marked gravity dependence, changes in position, can considerably impact oxygenation in approximately 75 percent of patients 28 .
Repositioning to the decubitus or prone position redistributes lung perfusion and can reduce the plateau airway pressure, despite reducing lung/chest wall compliance. Possible mechanisms for the improvement noted are recruitment of dependent lung zones, increased functional residual capacity (FRC), improved diaphragmatic excursion, increased cardiac output, and improved ventilation-perfusion matching. A multicenter randomized trial evaluating prone position for 6 hrs per day for 10 days found significant increase in Pao 2 /Fio 2 ratio but no survival benefit for patients with ARDS 29 . Complication from prone position include an increase in pressure sores at the new weight bearing sites-such as cheekbone, thorax, breast, iliac, crest and knee. As such, prone positioning appears safe and may be beneficial in patients with severe, refectory hypoxemia.
fluId MAnAgeMent
An ARDS Clinical Trials Network study of fluid conservative versus fluid liberal strategies in the management of patients with ARDS/ALI did not demonstrate a statistically significant difference in 60 day mortality when patients were stratified into either group 72 hours after presenting in ARDS 29 . However, patients treated with the fluid conservative strategy had an improved oxygenation index and lung injury score and an increase in ventilator-free days, without an increase in nonpulmonary organ failures. Maintaining a low-normal intravascular volume may be facilitated by hemodynamic monitoring with a central venous or Swan-Ganz catheter, aiming for a CVP or pulmonary capillary wedge pressure at the lower end of normal. Maintaining mean arterial pressure of 65-70 or more may then require pressor administration. Closely monitor urine output and administer diuretics to facilitate a negative fluid balance.
drug therAPy
No drug has proved beneficial in the prevention or management of ARDS. Systemic corticosteroids have been studied extensively for use in ARDS. A double-blind trial by the ARDS Network randomly assigned 180 patients with persistent ARDS to receive methylprednisolone or placebo for 21 days 30 . Persistent ARDS was defined as ongoing disease seven to 28 days after its onset. There was no difference in 60-day mortality (29.2 versus 28.6 percent) or 180-day mortality (31.5 versus 31.9 percent). Among patients randomized 7 to 13 days after the onset of ARDS, methylprednisolone caused a nonstatistically significant reduction in 60-day mortality (27 versus 36 percent) and 180-day mortality (27 versus 39 percent). Among patients randomized more than 14 days after the onset of ARDS, methylprednisolone increased 60-day mortality (35 versus 8 percent) and 180-day mortality (44 versus 12 percent). Methylprednisolone increased ventilator-free days, shock-free days, oxygenation, lung compliance, and blood pressure, but increased neuromuscular weakness. Several metaanalyses and reviews offer conflicting perspectives regarding corticosteroid treatment for ARDS. Points of debate include when to begin steroids, how long to give them, whether they should be tapered, and how to interpret subgroup analyses in published trials. Although some data suggest possible survival advantages when given early, particularly before two weeks have elapsed, ongoing controversy dictates the need for more research before definitive recommendations regarding corticosteroids can be made.
Numerous other pharmacologic therapies, including the use of inhaled synthetic surfactant, intravenous antibody to endotoxin, ketoconazole, and ibuprofen, have been tried and are not effective 31 . Small sepsis trials suggest a potential role for antibody to TNF and recombinant IL-1 receptor antagonist. Inhaled nitric oxide (NO), a potent pulmonary vasodilator seemed promising in early trials, but in larger controlled trials, did not change mortality rates in adults with ARDS 32 .
PrognosIs
Respiratory failure is not a common cause of death among patients with ARDS. One study of 47 patients with ARDS found that death during the initial three days was usually due to the underlying cause of the ARDS 33 . Later, most deaths were caused by nosocomial infections and/or sepsis. Only 16 percent of deaths were due to respiratory failure. Another study 34 reported that sepsis and multiple system organ failure were the most common cause of death among patients with ARDS (30 to 50 percent of cases). Respiratory failure was less common cause (13 to 19 percent). Risk factors for infection and/or multiorgan dysfunction syndrome are more powerful predictors of survival than are respiratory parameters. Numerous studies have documented advanced age, sepsis, and the presence of multiple organ dysfunction syndrome as connoting a poor outcome, probably because they predict death from nonrespiratory causes, which comprise the bulk of mortality 34 .
outcoMe
Survival has improved for patients with ARDS, with mortality rates falling to 25 to 30 percent in 2006 29, 35 . The reasons for the increased survival are unclear, but probably relate to improvements in supportive care and ventilatory strategies. Despite the severe lung dysfunction in ARDS, most survivors will have normal or nearly normal pulmonary function within 6-12 months. 36 A more difficult outcome to measure is quality of life following ALI. Survivors of ALI/ARDS have reported persistent symdrome such as cough, chest tightness, and wheezing, and score similarly to patients with serious chronic illness on validated health surveys. 37 
Key leArnIng PoInts
• Acute lung injury is an inflammatory process of damage to the alveolar-capillary membrane, which may be incited by a variety of initial insults.
• Acute respiratory distress syndrome describes patients at the most severe end of the spectrum of ALI.
• Both ALI and ARDS are commonly encountered in the ICu, and frequently go unrecognized.
• Clinicians should actively seek an alternative diagnosis when certain 'at-risk' conditions for ARDS -sepsis, pneumonia, aspiration -are absent, since specific, treatable conditions that mimic ARDS may present.
• Mechanical ventilation is the mainstay of therapy for ALI and ARDS ; tidal volumes should be 6 ml/kg of IBW or less, and P PLAT should be kept below 30 cm H 2 O.
• Positive end-expiratory pressure should be employed to keep the fraction of inspired oxygen (Fio 2 ) in the nontoxic range while achieving an arterial oxygen saturation above 87 percent.
• To date, no pharmacologic intervention has been proved to change the outcome of ARDS.
• Mortality in ARDS remains high at nearly 30 percent; long -term sequelae include dyspnea, neuromuscular weakness, and psychologic stress.
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